Cetirizine from topical phosphatidylcholine liposomes: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 8, 2004, Pages 359-366

  Elzainy, Abeer A W ^a   Gu, Xiaochen ^a   Simons, F Estelle R ^b   Simons, Keith J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antihistamine; Cetirizine; L phosphatidylcholine; Liposomes; Rabbits; Skin

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; LIPOSOME; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; EXPERIMENTAL DESIGN; LIPID VESICLE; NONHUMAN; RABBIT; RANDOMIZATION; SKIN TEST; URTICARIA;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; CETIRIZINE; DRUG HYPERSENSITIVITY; LIPOSOMES; RABBITS; SKIN ABSORPTION;

EID: 8844284470     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.419     Document Type: Article

References (33)

1. 1-Antihistamines in Allergic Disease, Simons FER (ed.). Marcel Dekker Inc: New York, 2002; 100-139.
2. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs 2001; 61: 2231-2240.
3. Meltzer EO, Grant JA. Impact of cetirizine on the burden of allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 455-463.
4. Canonica GW, Ciprandi G. Minimal persistent inflammation may be controlled by cetirizine. Ann Allergy Asthma Immunol 1999; 83 445-448.
5. 1-Antihistamines in Allergic Disease, Simons FER (ed.). Marcel Dekker Inc: New York, 2002; 437- 464.
6. Zyrtec® (Cetirizine 10mg) Tablets. PDR® Electronic Library, Thompson Medical Economics (2003) Accessed Aug. 2003.
7. Posner R. Liposomes. J Drugs Dermatol 2002; 1: 161-164.
8. New RC. Influence of liposome characteristics on their properties and fate. In Liposomes as Tools in Basic Research and Industry, Philippot JR, Schuber F (eds). CRC Press Inc: London, 1995; 3-20.
9. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001; 228: 43-52.
10. El-Ridy MS, Khalil RM. Free versus liposome-encapsulated lignocaine hydrochloride topical applications. Pharmazie 1999; 54: 682-684.
11. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 2002; 54 Suppl 1: S41-S55.
12. Betageri GV, Kulkarni SB. Preparation of liposomes. In Microspheres, Microcapsules and Liposomes: Preparation and Chemical Applications, Arshady R (ed.). Citus Books: London, 1999; 489-521.
13. Wertz PW. Epidermal lipids. Semin Dermatol 1992; 11 106-113.
14. Huston RL, Cypcar D, Cheng GS, Foulds DM. Toxicity from topical administration of diphenhydramine in children. Clin Pediatr 1990; 29: 542-545.
15. USP XXII, NFXVII, United States Pharmacopeial Convention, Inc. 22nd, 1990; 1785.
16. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 1973; 298: 1015-1019.
17. Nagarsenker MS, Londhe VY, Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm 1999; 190: 63-71.
18. Simons KJ, Elzainy AAW, Gu X, Simons FER. Effect of different phospholipids on the stability of liposomal formulations containing cetirizine. AAPS Pharm Sci 2003, Abstract T3272.
19. Watson WTA, Simons KJ, Chen XY, Simons FER. Cetirizine: A pharmacokinetics and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 457-464.
20. 1-receptor antagonists in the skin and serum. J Allergy Clin Immunol 1995; 95: 759-764.
21. 111In. Biochim Biophys Acta 1993; 1150: 162-164.
22. El Maghraby GMM, Williams AC, Barry BW. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm 2000; 196: 63-74.
23. Balen GPV, Caron G, Ermondi G, et al. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidy1choline liposomes/water systems. Pharm Res 2001; 18 694-701.
24. Nielsen PN, Skov PS, Poulsen LK, Schmelz M, Petersen Q. Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31: 1378-1384.
25. Foldvari M, Gesztes A, Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J Microencapsul 1990; 7: 479-489.
26. Bernard E, Dubois JL, Wepierre J. Importance of sebaceous glands in cutaneous penetration of an antiandrogen: Target effect of liposomes. J Pharm Sci 1997; 86: 573-578.
27. Tschan T, Steffen H, Supersaxo A. Sebaceous-gland deposition of isotretinoin after topical application: An in vitro study using human facial skin. Skin Pharmacol 1997; 10: 126-134.
28. Ogiso T, Yamaguchi T, Iwaki M, Tanino T, Miyake Y. Effect of positively and negatively charged liposomes on skin permeation of drugs. J Drug Target 2001; 9: 49-59.
29. Honzak L, Sentjure M, Swartz HM. In vivo EPR of topical delivery of a hydrophilic substance encapsulated in multilamellar liposomes applied to the skin of hairless and normal mice. J Control Release 2000; 66: 221-228.
30. Foong WC, Harsany BB, Mezei M. Biodisposition and histological evaluation of topically applied retinoic acid in liposomal, cream and gel dosage forms. In Phospholipids, Hanin I, Pepeu G (eds). Plenum Press: New York, 1990; 279-282.
31. Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 2004; 30: 289-296.
32. Mezei M, Gulasekharam V. Liposomes - a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980; 26: 1473-1477.
33. Patel HM. Liposomes as a controlled-release system. Biochem Soc Trans 1985; 13: 513-516.